Sero-epidemiology of rubella in the urban population of Addis Ababa Ethiopia by Cutts, Felicity et al.
  
University of Warwick institutional repository: http://go.warwick.ac.uk/wrap
This paper is made available online in accordance with 
publisher policies. Please scroll down to view the document 
itself. Please refer to the repository record for this item and our 
policy information available from the repository home page for 
further information.  
To see the final version of this paper please visit the publisher’s website. 
Access to the published version may require a subscription. 
 
Author(s):  F. T. CUTTS, A. ABEBE, T. MESSELE, A. DEJENE, F. 
ENQUSELASSIE, W. NIGATU and D. J. NOKES 
Article Title: Sero-epidemiology of rubella in the urban population of 
Addis Ababa Ethiopia 
Year of publication: 2000 
Link to published version: 
http://dx.doi.org/10.1017/S0950268899003532
Publisher statement: None 
 
 
 
Epidemiol. Infect. (2000), 124, 467–479. Printed in the United Kingdom # 2000 Cambridge University Press
Sero-epidemiology of rubella in the urban population of
Addis Ababa, Ethiopia
F. T. CUTTS"*, A. ABEBE#, T. MESSELE#, A. DEJENE#, F. ENQUSELASSIE$,%,
W. NIGATU# and D. J. NOKES%
"Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine,
Keppel St, London WC1E 7HT, UK
#Ethiopian Health and Nutrition Research Institute, PO Box 1242, Addis Ababa, Ethiopia
$Department of Community Health, Faculty of Medicine, Uniersity of Addis Ababa, PO Box 1176,
Addis Ababa, Ethiopia
%Ecology and Epidemiology Group, Department of Biological Sciences, Uniersity of Warwick,
Coentry, CV4 7AL, UK
(Accepted 20 Noember 1999)
SUMMARY
We conducted a community-based cluster sample survey of rubella sero-epidemiology in Addis
Ababa, Ethiopia in 1994. Among 4666 individuals for whom complete data were available,
rubella antibody prevalence was 91% (95% confidence interval : 90, 92). On multivariable
analysis, seroprevalence was lower among individuals who were resident in Addis Ababa for
1 year or less. Approx. 50% seroprevalence was attained by age 4 years, and the estimated
average age at infection was 5–2 years. The highest age-specific force of infection was estimated
to occur in 5- to 9-year-olds. The early age at infection corresponded with a low estimated
incidence of congenital rubella syndrome (CRS) of 0–3 per 1000 live births, equivalent to nine
cases of CRS in 1994. The predicted critical level of immunity for elimination of rubella via
vaccination was 85–91%, requiring 89–96% coverage with a vaccine of 95% effectiveness.
Unless very high coverage of rubella vaccine could be guaranteed, the introduction of
childhood vaccination could increase the incidence of CRS in Addis Ababa.
INTRODUCTION
Rubella vaccine has been available for over 30 years,
but as yet data on the burden of disease in developing
countries have been considered insufficient to make
global recommendations for its use [1]. The incidence
of congenital rubella syndrome (CRS) in outbreaks in
developing countries has been at least as high as that
in industrialized countries prior to vaccination [2]. All
countries which have documented large outbreaks of
CRS now have national rubella vaccination policies
[3]. The move in many countries towards accelerated
measles control and measles elimination raises the
question of the marginal cost of including rubella
* Author for correspondence.
control strategies with this initiative [4, 5]. Collection
of data on the burden of CRS in developing countries
is thus a priority [2, 3]. In countries where surveillance
of cases of CRS is poorly developed, serological
surveys of the age-specific prevalence of antibody
provide an alternative method of estimating the
burden of CRS [6–8]. We report findings from a large
community-based serosurvey of rubella immunity in
urban Ethiopia.
METHODS
A community-based cross-sectional survey was con-
ducted in Addis Ababa in May–October 1994. Full
details of the sample design and composition are given
elsewhere [9], and only briefly outlined here. Addis
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Ababa, the capital of Ethiopia, had an estimated
population in 1994 of approx. 2–1 million inhabitants,
having experienced high growth since the last census
in 1984, when the estimated population was
1–5 million. Administratively, it is divided into five
zones (ketenas), each of which is divided into woredas
(28 in total), which are further divided into kebeles or
urban dwellers’ associations. Each kebele consists of
approx. 2000 households, with an average of 5–2
persons per household [10]. A cluster sample survey
was conducted, 20 clusters being selected by Prob-
ability Proportional to Estimated Size sampling [11],
in each of two strata comprising the inner city and the
outer city. In each kebele, a random sample of 35
house numbers was selected. The lists of houses and
household numbers held at the kebele administrations
were used as the sample frame in the inner city. In the
outer city, where there is greater population mi-
gration, these lists were updated for the purpose of
this survey. Within each house selected, each house-
hold head was listed, and one household selected
randomly for registration in the study.
The sample size was based on the required precision
in each age category, by single years up to 4 years of
age, then 5 yearly age groups up to age 50, assuming
a design effect of two in the absence of data on intra-
cluster correlation of seropositivity [11]. A sample size
of 150 per age class would give estimates with
acceptable precision (7–12%) across the expected
range of seroprevalence. This sample size would be
obtained in a total sample of 1200 households in
Addis Ababa, equally divided between strata, i.e. 20
kebeles of 30 households in each stratum. This was
increased to 35 households per cluster to allow for up
to 15% non-participation in the survey. We requested
blood samples from all children aged under 5 years in
every household; 1 in 2 children of school-age
(5–14 years), selected randomly; and all adults aged
15–49 years.
All persons aged under 50 years who were part of
the selected household were invited to participate in
the study. Informed consent was obtained from the
head of the household. Persons who were visiting the
household and who slept in the selected house the
night before the survey were included. If all family
members were not present at the first visit, revisits
were made until all members had been interviewed
and samples obtained.
Two brief questionnaires were administered by
trained surveyors to each household. The first con-
tained information about each individual in the
household (age, sex, ethnic group, length of residence
in Addis Ababa, educational level, current school
attendance, history of measles and measles vacci-
nation). The second contained general information
about the household (type of construction, number of
rooms, type of roofing and floor material, source of
water, type of sanitation, etc.).
Approval for the survey was given by the Ethical
Committee of the Ethiopian Health and Nutrition
Research Institute (EHNRI), and St Mary’s Research
Ethics Committee, London University, UK.
Specimen collection and processing
Where possible, 5 ml of venous blood were obtained
from family members using sterile, disposable needles
(21–23G) and Vacutainers (Beckton Dickinson,
Banbury, England). Blood samples were transported
in cold boxes daily to the laboratory at EHNRI.
Serum samples were separated, aliquoted, labelled
and stored frozen at fi20 °C until analysis.
Laboratory assays
The laboratory was blind to the age of study
participants. All serum samples were tested for
rubella-specific IgG by radial haemolysis (RH) [7] and
results expressed in international units per ml (IU}ml).
As previously described [12], the detection limit of the
assay under routine use was 8–6 IU}ml. Serum samples
which were negative by RH (! 8–6 IU}ml) for which
sufficient residue was available were retested by
ELISA (Enzygnost anti-Rubella virus IgG, Dade
Behring, Milton Keynes, England); results also
expressed in IU}ml. Serum samples which were
negative by RH but with ELISA " 8–6 IU}ml were
tested by latex agglutination (LA) (Rubagen, Biokit
S.A, Barcelona, Spain) with sensitivity level of
15 IU}ml, if serum residue remained. Consensus
rubella antibody status based on agreement in two of
these tests was established.
Statistical analysis
Accounting for surey design
In our analyses of seroprevalence account was taken
of the survey design using STATA (V6–0) svy
commands following the procedure described in detail
elsewhere [9]. In brief, first, we applied probability
weights to each measurement to account for the
different population size in the inner and outer city
strata, and the variation in the number of households
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from each cluster (kebele) who participated, and
second, variance estimation took into account the
degree of inter- versus intra-cluster variability (i.e. the
lack of independence of samples within clusters) for
the first stage of cluster sampling where the kebele was
the primary sampling unit.
Classification of immunity to rubella
A positive RH test was taken as indicating immunity
to rubella. Of the 754 serum samples negative by RH,
644 had sufficient sera for ELISA testing and 255 were
positive. Of these, 249 could also be tested by LA and
229 were confirmed as positive and re-classified as
such. The 20 RH-negative, ELISA-positive and LA-
negative sera were classified as susceptible ; all had
low-level rubella antibody in the ELISA (mean
13 IU}ml). For analysis of factors associated with
seropositivity, the 117 RH-negative samples that were
not re-tested by ELISA and LA were excluded from
the analysis. For analysis of the force of infection and
incidence of maternal infection, we imputed the
antibody status of RH negative samples not repeat
tested by ELISA. For these samples, we assigned them
as ‘true’ positive or negative based on the age-
stratified proportion of samples which were negative
by ELISA and LA among those tested by both assays.
Factors associated with seropositiity
Cross-tables were conducted of demographic and
socio-economic variables against seropositivity and
the v# test used to assess significance. As this test does
not take the cluster sampling design into account, we
obtained an adjusted P value for factors showing an
apparent significant association using the svymean
command in stata. Factors significant on univariate
analysis were included in a logistic regression model
using stata svylogit command. A stepdown pro-
cedure was followed, dropping variables which did
not contribute significantly to the model.
Age-specific incidence of rubella and incidence of
maternal infection
Catalytic infection models were used to investigate
age-dependence in the instantaneous incidence of
rubella infection; also known as the force of infection
[13–16]. The analysis is based upon the following
assumptions: (i) the proportion serologically positive
at age a, p(a), defines the cumulative proportion
infected by age a, and further assumes that no
individual dies from post-natal rubella infection; (ii)
seropositivity is non-reversible, i.e. individuals cannot
revert from positive to negative; (iii) there has been no
significant change in the force of infection over time in
the population, such that differences in the force of
infection identified in the age-profile reflect age-related
rather than time-related changes in incidence. The
form of age-dependence in the force of infection
was identified in the data using graphical means
[13, 17], in particular the cumulative per person inci-
dence, G(a)flfiln(1fip(a)), and by examination of
point estimates of the force of infection calculated
directly from the data using the expression
kflfiln(x(a›Da)}x(a))}Da [18], where x(a)fl 1fi
p(a) is the proportion seronegative at age a and
Da is the age difference over which the force of
infection is being estimated. We subsequently applied
two models to the data. First, a piece-wise constant
(PWC) model [19] in which the force of infection, k
i
,
in age class i, is constant, but can vary between age
classes ifl 1, m, hence the predicted proportion
susceptible, x{(a)
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model describes an exponential decay in the pro-
portion seronegative between age a
iw"
and a where the
rate of decay is dependent upon the force of infection
applying in that age interval, k
i
. D is the average
duration of maternal antibody protection, taken to be
3 months (unpublished data from Addis Ababa
provided by Senait Kebede), and, for simplicity,
x(a)fl 0, p(a)fl 1, for D% 3 months. The proportion
seropositive, p{(a) is simply 1fix{(a).
Secondly, we assumed the force of infection, k(a), is
an exponentially damped linear (EDL) function of
age, a, as described by Farrington [13], such that
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Again, the proportion serologically positive is
p{(a)fl 1fix{(a). The model describes a decay, with
age, in proportion seronegative dependent upon a
force of infection that has an initial near linear rise
with age followed by a peak and subsequent expo-
nential decline (the value of b
#
in (2) defining the long
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term residual value of k(a)). The duration of maternal
antibody protection was implicitly modelled via the
assumption that k(0)fl 0.
Although the PWC model allowed for flexibility in
the form of age-dependence in the force of infection,
and also enabled us to assess the significance of model
fit to data as we increased the number of force of
infection age classes, it did require us to define the age
classes over which the force of infection applied (i.e.
the limits of the age classes were not variables whose
optimal solution was sought). The EDL model is not
constrained by pre-defined age classes, and also has
been shown to describe well the pattern of k(a) for a
variety of childhood viral infections in various settings
[13, 20].
Maximum-likelihood (ML) estimates (implicitly
weighting for sample size) for parameters in each
model were obtained using the procedure described by
Nokes and colleagues [15] within Microsoft excel
using the Quasi-Newton search method. In deriving
the 95% confidence intervals (CI) for each force of
infection estimate in the PWC model we assumed the
log-likelihoods approximate to a v# distribution [21].
Having obtained a ML fit to the data, we allowed a
single parameter estimate to vary (either increasing or
decreasing to obtain upper or lower confidence limits)
until the log-likelihood decreased by 1–92, keeping all
other parameters constant. Fixing the estimate of the
parameter of interest at this value we then allowed all
other parameters to vary to obtain a maximum-
likelihood fit to the data, and repeated the process
iteratively until no further change in the log-likelihood
occurred. We repeated this process to obtain 95% CI
for each of the parameters in turn. Validity of the
model fit to data was assessed graphically by the
scatter of standardized residuals of the form,
sfl
p(a)fip{(a)
o([p{(a)(1fip{(a))]}n)
, (4)
where p{(a) was the proportion seropositive by age a
predicted by the model [equations (1) or (2)], and n
was the sample size in age group a [15]. Comparison
of goodness of fit to the data between models was
made using the likelihood ratio test [21].
If we take the average gestation period to be 40}52
years then to a good approximation the number of
maternal infections per 1000 pregnancies can be
estimated by [19]
Mflxb [1fiexp (40k
"&
–
%*
}52)]‹1000, (5)
where k
"&
–
%*
was assumed to be a constant force of
infection acting on susceptibles in the child-bearing
age range 15–49 years, and xb the average predicted
proportion susceptible in this risk group. k
"&
–
%*
was
estimated from either the PWC [equation (1)] or EDL
[equation (2)] model, whichever provided the best fit to
the data, as the average force of infection over the at-
risk age interval. Implicitly we assumed that sero-
negativity equates with susceptibility to infection.
Since there is negligible probability of a fetal ab-
normality arising from primary rubella infection after
the first 16 weeks of pregnancy [22], and given a
weighted average probability of CRS over these 16
weeks of 0–65 [8], it follows that the estimated number
of CRS cases per 1000 pregnancies is
CRSfl 0–65xa [1fiexp (fi16k
"&
–
%*
}52)]‹1000. (6)
Approximate 95% CI can be estimated by substituting
into (5) or (6) the CIs for k
"&
–
%*
[19].
Summary epidemiological parameters
The average (arithmetic mean) age of infection, A,
across all ages at the time of a cross-sectional survey
was defined as [23]
Afl
&
¢
!
ak(a)X(a)da
&
¢
!
kX(a)da
. (7)
X(a)flx{(a)N(a) where x{(a) was predicted using
equations (1) or (3), and N(a) was the number of
individuals of age a in the urban population of Addis
Ababa, 1994. The solution to equation (7) was
approximated on excel (Microsoft Corporation)
using a discretized form with age interval of 0–1 year
and upper age of 99 years.
Making the simplifying assumption of an average
force of infection acting on susceptibles distributed
across all ages, then the Basic Reproduction Number
for rubella in Addis Ababa was approximated by the
expression [24, 25] :
R
!
E 1›
B
AfiD
, (8)
where B was the reciprocal of the crude birth rate
(CBR) per 1000 population per year, and assumed a
Type II mortality schedule (i.e. constant instantaneous
death rate across all ages). Census data show that in
1994 the population of Addis Ababa was pre-
dominated by young individuals (32% ! 15 years
old), which was an important determinant of the
average age at infection, A. Therefore, for a given
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Table 1. Uniariate analysis of potential factors associated with
seropositiity to rubella, Addis Ababa, 1994 (nfl 4549)
Variable Levels n
%
positive P (unadjusted)*
Age ! 15 1750 81–6 0–0000
15› 2799 96–9
Sex M 1813 90–6 0–7
F 2736 91–3
Sex, 15› yrs M 978 96–7 0–001
F 1821 93–8
Stratum Inner city 2359 89–5 0–03
Outer city 2190 87–5
Length of All life 2890 86–6 0–000
residence " 1 year 1454 93–5
% 1 year 205 81–5
Ethnic group 1, Amhara 2184 90–7 0–8
2, Oromo 789 90–6
3, Tigre 453 92–5
4, Gurage 830 91–2
5, Other 278 91–4
Education None 686 91–0 0–4
1–6 years 985 89–5
7–12 years 1103 91–6
" 12 years 544 91–4
Ownership of Rent}other 2655 91–1 0–9
house Own 1859 91–0
Type of wall Wood}bamboo}
canvass
4014 91–1 0–4
Bricks}stone 509 90–0
Type of roof Corrugated iron 4415 91–1 0–3
Stone}concrete}
tile
111 88–3
Number of people ! 5 658 90–6 0–3
in household 5–9 2616 90–6
10› 1275 92–1
Number of beds 0–1 912 89–4
2 1265 90–9 0–1
3› 2343 91–7
Electricity supply Private meter 3161 91–6 0–04
Other 1359 89–6
Ownership of No 717 89–5 0–1
radio Yes 3803 91–3
Source of water Public source 593 89–9 0–6
Shared tap 2028 91–2
Own tap 1898 91–1
Number sleeping % 2 1115 93–4 0–004
in same room 3–5 2223 89–8
& 6 1208 91–0
Number of 1 950 90–4 0–5
rooms 2 1580 90–7
3› 1994 91–5
* Adjusted P values as follows: Age; P!0–0001; sex (15›years) Pfl 0–001;
stratum, Pfl 0–02; residence, P! 0–0001, electricity supply, Pfl 0–08; number
sleeping in same room, Pfl 0–0001, for comparison between 3–5, and ! 3 people.
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Fig. 1. Age-prevalence of rubella specific antibodies (95% confidence limits) in a representative sample of individuals
(nfl 4666) from Addis Ababa 1994. Age groups are yearly up to age 14, and 5-yearly thereafter.
reproductive capacity of the infection (R
!
), the higher
the proportion in the younger age classes, the lower
the average age at infection. This explains why the
term B is present in equation (8), such that a low
average age at infection may not in itself reflect a high
R
!
, rather a low A may reflect low B (high CBR).
However, census data over the past 30 years indicated
the CBR in Addis Ababa to have fallen from 35–5 in
1967, to 32–2 in 1974, to 23–2 in 1984, to 15–5 in 1994.
Hence to take account of this changing pattern we
estimated R
!
using a range of values of B derived from
average CBRs for the periods 1967–74, 1974–84,
1984–94, which are, 29–4, 37–0 and 53–8 years, re-
spectively.
From equation (8) the critical level of immunity
above which infection was predicted to be eliminated
by vaccination (the herd immunity threshold), was
defined as [26]
Hfl 1fi1}R
!
. (9)
RESULTS
A total of 8638 persons were registered in the study.
Of these, serum samples were obtained from 4777 but
for 97 insufficient was available for analysis ; a further
5 were excluded because the identification number did
not match that on the questionnaire. Of the 4675
individuals with adequate serology and questionnaire
information, 9 were excluded because of missing data
on age. The characteristics of the sample in com-
parison to the census data for Addis Ababa have been
presented in detail elsewhere [9] ; in general, adult men
were under-represented.
Factors associated with seropositivity
Of the 4666 serum samples 746 (16%) were negative
by RH assay. However, a substantial number of these
were false negatives, and after adjustment for results
of repeat assays, 409 (9%) of 4549 sera were negative
in at least two of the three assays. The unweighted
proportion seropositive was thus 91%. The weighted
seroprevalence, accounting for cluster size and
stratum, was virtually unchanged at 90–9% (95% CI,
89–9, 91–9%). The estimated design effect (the ratio of
the standard error in a cluster survey to that which
would have been obtained with a simple random
sample of the same size) was 1–42.
Table 1 presents results of univariate analysis of
factors associated with seropositivity. Overall, there
was no difference in seropositivity by sex. When
adults over 14 years were examined, seroprevalence
was slightly but significantly lower in women (93–8%
s. 96–7%, Pfl 0–0001). Seroprevalence was higher in
persons who had lived in Addis Ababa more than one
year but less than lifelong. This relationship was
confounded by age and sex, however, more adult
males being in this group. Individuals who slept in
rooms with more than two other persons were less
likely to be seropositive on univariate analysis, but
this was confounded by age as these were more likely
to be children. Seroprevalence was slightly higher in
the inner than outer city (89–5 s. 87–5%, Pfl 0–03).
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Fig. 2. Modelling age-prevalence of rubella. (a) Cumulative
incidence of rubella as a function of age, G(a). (b) Point
estimates of age-specific forces of infection (}year). (c)
Maximum-likelihood fit of a minimally specified (3 param-
eter) piece-wise constant (PCW) model [thick line, equa-
tion (1)] and an exponentially damped linear [EDL, equation
(3)] model (thin line) to rubella age-prevalence data from
Addis Ababa, 1994 (open markers). Sample sizes for each
age class from 0, 49 years : 56, 68, 71, 97, 125, 109, 92, 141,
126, 145, 176, 116, 180, 155, 157, 134, 224, 156, 219, 153,
175, 90, 141, 97, 96, 136, 53, 75, 82, 42, 118, 28, 70, 32, 31,
133, 46, 51, 73, 21, 103, 16, 31, 23, 18, 91, 19, 15, 30, 30.
Seroprevalence varied little and was not significantly
associated with ethnic group or indicators of socio-
economic status such as education, household size,
type of housing or roof construction, number of
rooms in the house, ownership of the house, number
of beds owned, possession of a radio, or presence of
piped water in the house.
On logistic regression, in addition to the interaction
term for age (adult s. child) and sex, only length of
residence in Addis Ababa remained significantly
associated with seropositivity. Adults were more likely
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!
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b
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#
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(adjusted data, dashed line). In (b) average values of k are
shown for age classes corresponding to those in (a) for
comparison.
to be seropositive than children (OR 14–4 for men, 6–2
for women (P! 0–0001)) and individuals who had
lived a year or less in Addis Ababa were less likely to
be seropositive (OR 0–45, Pfl 0–0001).
Age-specific incidence of rubella
Seroprevalence increased sharply up to age 8 years,
when 94% were seropositive. After this age there was
a very slow increase, and 98% of 45- to 49-year-olds
were seropositive (Fig. 1).
Preliminary examination of the total (males and
females) data using the cumulative incidence function
G(a) (Fig. 2a) and point estimates of k(a) (Fig. 2b)
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suggests three phases in the force of infection by age
namely, low and rising in early childhood (0–25–4
years), highest in age range 5–9 years, and decreasing
to low level in the age class 10–49 years. Using these
age groups as a baseline we explored the data using
the PWC model, and assessed the improvement in
model fit for fewer age classes or for an increase in
classes using the following range: ifl 0–25 to ! 1, 1, 2,
3, 4, 5–9, 10–14, 15–19, 20–29, 30–49 years. Figure 2c
shows the maximum-likelihood fit of the minimally
specified PWC model (thick line) to the raw data with
three force of infection age classes (0–25–4, 5–9, 10–49
years). Reduction, or addition, of further age classes
showed no statistical improvement in log-likelihood
ratio. The maximum-likelihood fit of the EDL model
to the data is shown by the thinner line in Figure 2c.
The corresponding scatter of standardized residuals
for each model fitted to the data suggests a better
overall explanation of the data by the PWC model
compared with the EDL model (not shown), and this
is supported by a significantly lower log-likelihood
value for the PWC model (fi2‹log-like PWC
2050.29; EDL 2066.71; both models have three
parameters and hence are comparable using log-
likelihoods).
The corresponding maximum-likelihood estimates
of the age-dependent forces of infection (}suscept-
ible}year) for rubella are given in Figure 3 (solid
lines). Figure 3a shows the k
i
estimates for the PWC
model (with 95% CI), and Figure 3b shows k(a) for
the EDL model (with bars showing averages over the
same age ranges as in graph a ; 95% CI for each
parameter are given in the figure legend). The
relationship with age is similar for both models, with
markedly higher instantaneous incidence in children
(! 10 years) relative to older ages, although the peak
force of infection of 0–42}susceptible person per year
for the PWC model in the age class 5–9 years is higher,
and in an older age class, than the peak of 0–31 at age
4 years for the EDL model.
Antibody levels (GMT) showed a decline with age
primarily over the age range 1–20 years, with little
evidence of further decline in the age group 20–49
years (Fig. 4a), although the variation in antibody
levels (log-transformed, Fig. 4b) continued to rise
throughout the age range. Log-transformed antibody
levels showed a near normal distribution for each age
class (not illustrated), and on this basis we estimated
proportion of previously seropositive individuals predicted to be falsely antibody-negative given a threshold antibody level
of 8–6 (thick lower line) or 15 (thin upper line) IU}ml. Analysis excludes individuals with antibody levels ! 8–6 IU}ml (i.e.
seronegative), and age classes merged where sample size was lower than 50.
the proportion of individuals with previously de-
tectable antibody levels expected to have levels which
have decayed below a defined threshold (8–6 or
15 IU}ml). Figure 4c shows that this proportion rises
throughout the age range, such that for adults
("20 years) around 1–2% are predicted to have levels
less than 8–6 IU}ml (thick line) and 3–5% less than
15 IU}ml (thin line).
Using the data shown in Figure 4c with threshold
8–6 IU}ml, we computed the expected number of false
negatives for the sample of positives in each age class
and adjusted the observed numbers accordingly.
Revised estimates of the age-specific forces of infection
are shown as dotted lines in Figures 3a, b, and reveal
the most significant change in the older age class, with
over 50% increase in the estimated force of infection.
Predicted incidence of maternal rubella and CRS
Separate analyses for males (dark grey) and females
(light grey) using the PWC model with three age
classes yield estimates of k
i
shown in Figure 5 for raw
data (solid bars) and data adjusted for false negatives
(dashed bars). Based upon equations (5) and (6) we
predicted the number of cases of primary maternal
infection to be about 1}1000 pregnancies or 33–35 in
total in Addis Ababa 1994 (assuming 32237 births in
Addis Ababa in 1994 reported in the 1994 census),
resulting in an estimated 9 (95% CI: 5, 13) cases of
CRS in 1994 (Table 2). There was little difference in
the results using the raw data or that adjusted for false
negatives [the higher force of infection from adjusted
data is balanced by a smaller fraction susceptible
(Table 2)]. Note that these estimates based upon the
adjusted data make the assumption that individuals
whose antibody levels have waned below the level of
detection remain immune to re-infection.
Summary epidemiological parameters
Approx. 50% of individuals have evidence of past
infection by age 4 years (Fig. 1, 2c). The estimated
average age at infection from equation (7) is 5–2 years.
From equation (8) and adopting a range of values of
B (1}CBR), the estimated basic reproduction number,
R
!
, lies within the range 6–9 and 11–8 (the latter
assuming more recent lower CBR, thus higher B),
with corresponding estimates of the critical level of
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effective immunity through vaccination for elimin-
ation, H, of 85–91%.
DISCUSSION
In our large community-based study of rubella sero-
epidemiology, immunity to rubella was acquired early
in life, with 94% of 8 year old children having
detectable antibodies. The low estimated average age
at infection of around 5 years reflects in part the high
k estimates and in part the demographic charac-
teristics of this population, where 32% are under
15 years old. The average age at infection is higher
than that of 2–3 years estimated in The Gambia in
1976 [23], but lower than other published estimates of
6 years in Brazil [27], 8 years in Mexico [28] or
9–12 years in England and Wales, Germany and the
USA in the pre-vaccination era [18]. Correspondingly,
the basic reproductive rate, R
!
, estimated from our
study (6–9–11–8) is somewhat higher than the 6–7
estimated previously for England and Wales and
Germany, but lower than that in The Gambia [23].
Estimates of R
!
reported here are very approximate as
they do not account for age-heterogeneity in trans-
mission [23] and because of the changing demographic
pattern; assumptions about the timing of the decline
in birth rate having relatively large effects on the
average age of infection and R
!
. However, our
approximate estimates of R
!
between 7 and 12 suggest
a level of immunity for elimination of around
85–91%. Rubella vaccine is highly immunogenic,
most studies showing at least 95% seroconversion [3].
Given a vaccine of 95% effectiveness, the level of
coverage required would be 89–96%. This compares
to the current reported level of measles vaccination
coverage in Addis Ababa of 80–85% and in Ethiopia
as a whole of 52% (WHO, unpublished data, 1997).
Data on the seroprevalence of rubella in Addis
Ababa, which is a very densely populated city, cannot
be extrapolated to the whole of Ethiopia. A WHO
collaborative study in the Americas in 1967–8 showed
urban–rural differences in susceptibility to rubella of
43 s. 51% in Jamaica, 38 s. 65% in Panama, and 22
s. 40% in Peru [29]. In contrast, results from the
same collaborative study in Argentina, Brazil, Chile,
Trinidad and Tobago, and Uruguay showed few
urban–rural differences, and Gomwalk and colleagues
[30] found no urban–rural differential in Imo State,
Nigeria. Preliminary data from a study in one rural
area of Ethiopia show that while rubella seropositivity
increases slightly more slowly than in Addis Ababa,
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Fig. 5. Age- and sex-specific forces of rubella infection (95% CI) in Addis Ababa, 1994, estimated using a PWC catalytic
infection model [equation (1)]. Males (dark bars), females (light bars), raw data (full bars), adjusted data (dashes).
" 90% of 10- to 19-year-olds are immune [12]. Our
finding of a significant association between residence
for more than one year in Addis Ababa and
seropositivity supports the likelihood of a higher force
of infection in Addis Ababa than elsewhere in
Ethiopia.
The significantly lower proportion seropositive in
adult women than men is difficult to explain, as it
remained significant after including length of residence
in the model. Repeated exposure to rubella via contact
with children would normally be higher in women, but
in the crowded urban environment exposure was
likely to be high for everyone. The absolute difference
in seroprevalence was small (2%). If our estimates for
the age-specific probability of false negatives are
correct (1–2% in individuals 20–49 years) then, after
adjustment, this difference becomes negligible, with
the result that there is no difference in the force of
infection for adults between the sexes (see Fig. 5). The
estimated force of infection in adult women was low
[kfl 0–04}year (raw data), 0–06 (adjusted)] and only
3–3% (2–4%) of women were considered susceptible to
rubella, with a correspondingly low estimated inci-
dence of maternal infection and an estimated total of
nine CRS cases in Addis Ababa in 1994. This is
similar to the estimate of maternal infection of
1–3}1000 in Sao Paulo, Brazil and 1–2 in Cordoba
State, Mexico but lower than that in other African
countries (Co# te d’Ivoire, Gabon, Nigeria and Zambia)
for which thes estimates were available [8]. While
some cases of CRS will be expected, the public health
burden is relatively low, and it would be hard to
improve on the immunity profile of adults acquired
via natural infection through a vaccination pro-
gramme in this low income country. Results from the
analysis of Anderson and May [18, 23], bearing in
mind various simplifying assumptions they make
(age-independent mixing and mortality), suggest that
with an Afl 3–6, infant vaccination will (in the long
term) worsen the pre-vaccination incidence of CRS,
potentially many-fold, until effective vaccination
coverage approaches the critical level for elimination
(of around 90% in Addis Ababa).
There are constraints on the use of data from a
cross-sectional survey to estimate the transmission
dynamics of rubella. Epidemics of rubella occur at
varying intervals, usually of 4–6 years [2], causing
variation in the age-specific prevalence of rubella
antibody over time. However, since seroprevalence
reflects cumulative exposure over time}age, the impact
of the epidemic nature of infection will be observable
predominantly in the younger ages. Thus, the period-
icity of epidemics is unlikely to change the finding that
most persons acquire infection before childbearing
age in Addis Ababa. We used the radial haemolysis
test to quantify rubella antibody levels in sera. This is
an inexpensive test that was easy to establish in
Ethiopia, and has been well evaluated in previous
studies [7]. We have found that the RH assay tends to
give negative results in adults who are sero-positive by
ELISA and presumably have relatively low antibody
levels reflecting waning immunity [12]. Hence we
confirmed negative samples using an ELISA and latex
agglutination. The use of a cut-off of 8–6 IU}ml is
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comparable to most commercial ELISA methods, and
is similar to the threshold for rubella immunity of
10 IU}ml suggested by others [20, 31].
The implications for rates of transmission and CRS
incidence of an increase in the probability of false-
negative individuals with increasing age, estimated
from this study, are dependent upon our assumptions
about immunity in these individuals. Although
reinfection has been documented in individuals with
low antibody levels, it appears to result in a low-grade
viraemia, with a much reduced risk of transmission to
contacts or to a fetus [32, 33]. Rare CRS cases have
nonetheless been documented in vaccinated women
known to have been seropositive on at least one
previous occasion [34].
Age-dependence in the force of infection has not
previously been so thoroughly investigated in a
developing country setting. Elucidation of age
differences requires large sample sizes over a wide age
range and fine age stratification, ideally from rep-
resentative samples of the population under study.
Such studies are few [7, 20, 35]. A functional form for
age-dependence in k put forward by Farrington [13]
and shown to fit data from widely different locations
of England and Wales and Sao Paulo, Brazil, was
unable to describe data from Addis Ababa adequately.
There was no statistical evidence for a rise in k over
the 0–4 years age group, or for any differences in k in
10› years ages. The clear distinction in k between 1-
to 4-year-olds and 5- to 9-year-olds may reflect school
attendance, and the decrease into teenages and
adulthood reflect fewer infectious contacts within
these age groups due to the dwindling supply of
susceptibles.
In the past, rubella has not been considered a public
health priority in developing countries, and this is still
appropriate in the poorest countries that have high
infant, child and maternal mortality and poor infra-
structure for health and education services. However,
developing countries span a wide range of economies
and demographic structures. Outbreaks of CRS are
highly distressing to parents and health professionals.
As more countries introduce rubella vaccine into their
routine immunization programme, there will be
increasing pressure to include rubella vaccine in the
global Expanded Programme on Immunization. It
would be difficult and expensive to obtain data on the
current burden of CRS in every country, on which a
policy decision about vaccination could be made at
the local level. It is more likely that recommendations
will follow regional or global priorities and, should a
global measles eradication goal be declared, the
inclusion of rubella vaccine would be attractive.
Nonetheless, our results demonstrate that it is es-
sential that any country planning to introduce rubella
vaccine must have the economic, logistical and
technical capacities and commitment to sustain and
monitor an effective programme.
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